Nurul Cholifah Lutfiana

Nurul Cholifah Lutfiana

Auto-generated profile, based on publicly available information

Nurul Cholifah Lutfiana

Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2019 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
NLNurul Cholifah Lutfiana
Nurul Cholifah Lutfiana
Job van BovenJob van Boven
Job van Boven
MZMuhammad Asim Masoom Zubair
Muhammad Asim Masoom Zubair
MPMichelle J. Pena
Michelle J. Pena
JAJan-Willem C Alffenaar
Jan-Willem C Alffenaar
Aims: With a prevalence of 16%, diabetes mellitus (DM) is one of the most frequent non‐communicable comorbidities of tuberculosis (TB). DM is a major risk factor for adverse TB outcomes and may require personalized TB drug dosing regimens. However, information on the inclusion of DM in TB drug trials is lacking. We aimed to assess the percentage of recent TB drug efficacy trials that included DM patients.Methods: A systematic review was performed and reported according to PRISMA guidelines. PubMed, Science Direct, and ClinicalTrials.gov databases were systematically searched for TB drug trials published between 1 January 2012 and 12 September 2017. Primary outcome was the percentage of TB drug trials performed around the world that included DM patients.Results: Out of the included 41 TB drug trials, 12 (29.3%) reported DM comorbidity among the study participants. Nine trials (21.9%) excluded all patients with DM comorbidity, ten (24.4%) excluded only insulin‐dependent or uncontrolled DM, and 10 (24.4%) did not mention whether DM was included or excluded. Of the 12 trials that included DM comorbidity, the majority did not report the diagnostic criteria for DM and none reported outcomes in the DM subpopulation. Inclusion of DM was higher in drug‐resistant‐TB trials (67%, P = .003, vs drug‐susceptible) and trials performed in Asia (60%, P = .006, vs Africa).Conclusions: Fewer than 1/3 recent TB drug trials reported the inclusion of DM. To better reflect real‐world DM prevalence and differential TB drug effectiveness, inclusion of DM patients requires increased attention for future TB drug trials.

1 April 2018 in Endocrine Regulations
Verified
Journal Article
Open access
PDF file
TWTitin Andri Wihastuti
Titin Andri Wihastuti
THTeuku Heriansyah
Teuku Heriansyah
HHHanifa Hanifa
Hanifa Hanifa
SASri Andarini
Sri Andarini
ZSZuhrotus Sholichah
Zuhrotus Sholichah
NLNurul Cholifah Lutfiana
Nurul Cholifah Lutfiana
Objective. Increase in the low-density lipoprotein (LDL) level in diabetes mellitus and atherosclerosis is related to lipoprotein associated phospholipase A2 (Lp-PLA2). Lp-PLA2 is an enzyme that produces lysophosphatidylcholine (LysoPC) and oxidized nonesterified fatty acids (oxNEFA). LysoPC regulates inflammation mediators, including intra-cellular adhesion molecule-1 (ICAM-1). Darapladib is known as a Lp-PLA2 specific inhibitor. The aim of this study was to reveal the effect of darapladib on the foam cell number, inducible nitric oxide synthase (iNOS), and ICAM-1 expression in aorta at early stages of the atherosclerosis in type 2 diabetes mellitus Sprague-Dawley rat model. Methods. Thirty Sprague-Dawley male rats were divided into 3 main groups: control, rats with type 2 diabetes mellitus (T2DM), and T2DM rats treated with darapladib (T2DM-DP). Each group was divided into 2 subgroups according the time of treatment: 8-week and 16-week treatment group. Fasting blood glucose, insulin resistance, and lipid profile were measured and analyzed to ensure T2DM model. The foam cells number were detected using hematoxylin-eosin (HE) staining and the expression of iNOS and ICAM-1 was analyzed using double immunofluorescence staining. Results. Induction of T2DM in male Sprague-Dawley rats after high fat diet and streptozotocin injection was confirmed by elevated levels of total cholesterol and LDL and increased fasting glucose and insulin levels compared to controls after both times of treatment. Moreover, T2DM in rats induced a significant increase (p<0.05) in the foam cells number and iNOS and ICAM-1 expression in aorta compared to controls after both treatment times. Darapladib treatment significantly reduced (p<0.05) foam cells number as well as iNOS expression in aorta in rats with T2DM after both treatment times. A significant decrease (p<0.05) in ICAM-1 expression in aorta was observed after darapladib treatment in rats with T2DM only after 8 weeks of treatment. Conclusion. Our data indicate that darapladib can decrease the foam cells number, iNOS, and ICAM-1 expression in aorta at the early stages of atherosclerosis in T2DM rat model.

24 October 2018 in The Open Medicinal Chemistry Journal
Verified
Journal Article
Open access
PDF file
TWTitin Andri Wihastuti
Titin Andri Wihastuti
FAFitria N. Aini
Fitria N. Aini
NLNurul C. Lutfiana
Nurul C. Lutfiana
THTeuku Heriansyah
Teuku Heriansyah
NZNafisatuz Zamrudah
Nafisatuz Zamrudah
This study is aimed to examine the expression of ICAM-1 and VCAM-1 in cardiac tissue of dyslipidemic Sprague Dawley rats. Eight Sprague Dawley strain rats, with 150-200 gram body weight, were divided into two groups. The control group was fed a standard diet, the positive control group was fed a high-fat diet as our previous study for 8 weeks. The pattern of distribution of ICAM-1 and VCAM-1 in cardiac muscle cell was examined by immunofluorescence and observed with a confocal laser scanning microscope. Lipid profile was also examined at the end of the study. Independent t-test showed no differences in ICAM-1 and VCAM-1 expression in cardiac muscle of hypercholesterol-diet-fed Sprague Dawley rat compared to control. The expression of ICAM-1 and VCAM-1 in cardiac muscle did not change after the onset of atherosclerosis.

15 March 2018 in International Journal of Pharmacology
Verified
Journal Article
Closed access
THTeuku Heriansyah
Teuku Heriansyah
NLNurul Cholifah Lutfiana
Nurul Cholifah Lutfiana
YSYuni Hendrati Sulfia
Yuni Hendrati Sulfia
ZSZuhrotus Sholichah
Zuhrotus Sholichah
RLRosaria Dian Lestari
Rosaria Dian Lestari
TWTitin Andri Wihastuti
Titin Andri Wihastuti
Inhibition of Adhesion Molecule Expression in Early Progression of Atherosclerosis in Dyslipidemia Model on Sprague Dawley Rats by Darapladib

1 January 2022 in Open Access Macedonian Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
YYYuyun Yueniwati
Yuyun Yueniwati
MSMokhamad Fahmi Rizki Syaban
Mokhamad Fahmi Rizki Syaban
Athaya Febriantyo PurnomoAthaya Febriantyo Purnomo
Athaya Febriantyo Purnomo
EKEdwin Kinesya
Edwin Kinesya
YMYusuf Mannagalli
Yusuf Mannagalli
APAdilla Shafryantyo Purnomo
Adilla Shafryantyo Purnomo
BACKGROUND: Anticoagulant therapy is recommendation for COVID-19 infection. However, the mechanical ventilation needed for COVID-19 is still high. AIM: The aim of the study was to determine comparison therapeutic and prophylactic dose LMWH for mechanical necessity in COVID-19 infection. METHODS: A systematic literature search articles online from studies published between 2020 and 2021 that met our inclusion criteria and were retrieved from scientific databases such as Cochrane, ProQuest, and PubMed. The primary measure was a composite bad outcome, which included mechanical ventilation, mortality. and bleeding risk. RESULTS: There were 3432 patients from seven study included in this meta-analysis for necessity of mechanical ventilation in COVID-19 patients that used prophylactic and therapeutic anticoagulants. Prophylactic dose of anticoagulant showed no difference for the need for mechanical ventilation necessity for COVID-19 patients (RR = 0.54; 95% CI = 0.20–1.48; p = 0.23). However, prophylactic anticoagulant showed more safe for bleeding incidence (RR = 0.27; 95% CI = 0.18–0.39; p = <0.00001) and reduce mortality (RR = 0.52; 95% CI = 0.46-0.58; p = <0.00001). CONCLUSION: LMWH anticoagulant dose not associated with reduce mechanical ventilation necessity but prophylactic dose prefers rather than therapeutic dose for reduce mortality and risk of bleeding.